Results 141 to 150 of about 669,633 (262)

Iron(III)‐loaded cation exchange resin: A dual approach for aqueous H2S removal and biogas desulphurization

open access: yesThe Canadian Journal of Chemical Engineering, EarlyView.
Left: Desulphurization method application. Right: Novel desulphurization method. Abstract The presence of hydrogen sulphide (H2S) in biogas poses significant environmental and operational challenges due to its corrosive and toxic properties. Thus, this study aimed to develop a dual‐function desulphurization system using a cation exchange resin (CIER ...
Matheus Damásio Thrun   +6 more
wiley   +1 more source

Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Dupilumab, a fully human monoclonal antibody that blocks key drivers of type 2 inflammation, is approved across 8 diseases, including eosinophilic esophagitis. Subcutaneous dupilumab 300 mg weekly improved outcomes vs. placebo in adults (aged ≥ 18 years) and adolescents (aged ≥ 12 to < 18 years) during the phase III LIBERTY EoE TREET study (NCT03633617)
Jenny‐Hoa Nguyen   +8 more
wiley   +1 more source

Mediterranean Botany: plant sciences for the Mediterranean biomes [PDF]

open access: yes, 2018
Gavilán, Rosario   +1 more
core   +2 more sources

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh   +4 more
wiley   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy